학술논문
Memsorb™, a novel CO2 removal device part II: in vivo performance with the Zeus IE®
Document Type
Original Paper
Author
Source
Journal of Clinical Monitoring and Computing. 36(6):1647-1655
Subject
Language
English
ISSN
1387-1307
1573-2614
1573-2614
Abstract
Memsorb™ (DMF Medical, Halifax, Canada) is a novel device based upon membrane oxygenator technology designed to eliminate CO2 from exhaled gas when using a circle anesthesia circuit. Exhaled gases pass through semipermeable hollow fibers and sweep gas flowing through these fibers creates a diffusion gradient for CO2 removal. In vivo Memsorb™ performance was tested during target-controlled closed-circuit anesthesia (TCCCA) with desflurane in O2 /air using a Zeus IE® anesthesia workstation (Dräger, Lübeck, Germany). Clinical care protocols for using this novel device were guided by in vitro performance results from a prior study (submitted simultaneously). After IRB approval, written informed consent was obtained from 10 ASA PS I–III patients undergoing robot-assisted radical prostatectomy. TCCCA targets were 39% inspired O2 concentration (FI O2 ) and 5.0% end-expired desflurane concentration (FET des). Minute ventilation (MV) was adjusted to maintain 4.5–6.0% FET CO2 . The O2 /air (40% O2 ) sweep flow into the Memsorb™ was manually adjusted in an attempt to keep inspired CO2 concentration (FI CO2 ) ≤ 0.8%. The following data were collected: FI O2 , FET des, FI CO2 , FET CO2 , MV, fresh gas flow (FGF, O2 and air), sweep flow, and cumulative desflurane usage (Vdes). Vdes of the Zeus IE®—Memsorb™ combination was compared with historical Vdes observed in a previous study when soda lime (DrägerSorb 800 +) was used. Results are reported as median and inter-quartiles. A combination of manually adjusting sweep flow (26 [21,27] L/min) and MV sufficed to maintain FI CO2 ≤ 0.8% and FET CO2 ≤ 6.0%, except in one patient in whom the target Zeus IE® FGF had to be increased to 0.7 L/min for 6 min. FI O2 and FET des were maintained close to their targets. Zeus IE® FGF after 5 min was 0 [0,0] mL/min. Average Vdes after 50 min was higher with Memsorb™ (20.3 mL) compared to historical soda lime canister data (12.3 mL). During target-controlled closed-circuit anesthesia in patients undergoing robot-assisted radical prostatectomy, the Memsorb™ maintained FI CO2 ≤ 0.8% and FET CO2 ≤ 6.0%, and FI O2 remained close to target. Modest amounts of desflurane were lost with the use of the Memsorb™. The need for adjustments of sweep flow, minute ventilation, and occasionally Zeus IE® FGF indicates that the Memsorb™ system should preferentially be integrated into an automated closed-loop system.